Empowered Funds LLC Purchases New Stake in IonQ, Inc. $IONQ

Key Points

• Empowered Funds LLC acquired 73,687 IonQ shares during the second quarter, valued at approximately $3.93 million. Institutional investors and hedge funds collectively own 41.42% of the company.
• IonQ reported stronger-than-expected quarterly results, with revenue of $80.05 million—up 286.7% year over year—and an adjusted loss of $0.33 per share versus analysts’ expected loss of $0.56.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $69.92, although IonQ remains unprofitable and recent insider sales and potential warrant-related dilution present risks.

Empowered Funds LLC acquired a new position in shares of IonQ, Inc. (NYSE:IONQ - Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 73,687 shares of the company's stock, valued at approximately $3,925,000.

Other large investors also recently made changes to their positions in the company. Beaird Harris Wealth Management LLC grew its holdings in IonQ by 117.4% during the 3rd quarter. Beaird Harris Wealth Management LLC now owns 500 shares of the company's stock valued at $31,000 after purchasing an additional 270 shares in the last quarter. EFG International AG purchased a new position in IonQ in the 2nd quarter valued at about $30,000. Accent Capital Management LLC boosted its position in IonQ by 171.8% in the 4th quarter. Accent Capital Management LLC now owns 587 shares of the company's stock valued at $26,000 after buying an additional 371 shares during the last quarter. Kelleher Financial Advisors acquired a new stake in shares of IonQ during the third quarter valued at about $36,000. Finally, Banque Transatlantique SA acquired a new stake in shares of IonQ during the third quarter valued at about $43,000. Institutional investors and hedge funds own 41.42% of the company's stock.

Insider Buying and Selling at IonQ

In other news, insider John W. Raymond sold 3,815 shares of the firm's stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $55.01, for a total value of $209,863.15. Following the sale, the insider directly owned 80,148 shares of the company's stock, valued at approximately $4,408,941.48. This trade represents a 4.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gabrielle B. Toledano sold 2,757 shares of IonQ stock in a transaction dated Thursday, June 18th. The stock was sold at an average price of $55.01, for a total value of $151,662.57. Following the completion of the transaction, the director owned 11,154 shares in the company, valued at $613,581.54. The trade was a 19.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 9,329 shares of company stock worth $513,216 over the last ninety days. Company insiders own 0.55% of the company's stock.

IonQ Stock Down 3.7%

Shares of IONQ stock opened at $37.87 on Wednesday. IonQ, Inc. has a 12 month low of $25.89 and a 12 month high of $84.64. The company has a market cap of $14.43 billion, a PE ratio of -8.13 and a beta of 3.30. The business's 50 day moving average is $41.98 and its two-hundred day moving average is $43.48.

IonQ (NYSE:IONQ - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.33) earnings per share for the quarter, topping analysts' consensus estimates of ($0.56) by $0.23. IonQ had a negative net margin of 553.27% and a negative return on equity of 22.29%. The business had revenue of $80.05 million during the quarter, compared to analysts' expectations of $66.47 million. During the same period in the previous year, the company earned ($0.70) earnings per share. IonQ's revenue for the quarter was up 286.7% on a year-over-year basis. As a group, equities analysts expect that IonQ, Inc. will post -2.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on IONQ shares. Jefferies Financial Group set a $75.00 price target on shares of IonQ in a research report on Thursday, August 6th. Rosenblatt Securities reiterated a "buy" rating and set a $100.00 price objective on shares of IonQ in a research report on Thursday, August 6th. JPMorgan Chase & Co. lifted their price objective on shares of IonQ from $42.00 to $50.00 and gave the stock a "neutral" rating in a research report on Thursday, May 7th. Wedbush initiated coverage on shares of IonQ in a research note on Monday, August 3rd. They set an "outperform" rating and a $75.00 target price on the stock. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $70.00 target price on shares of IonQ in a report on Thursday, August 6th. Nine research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, IonQ currently has an average rating of "Moderate Buy" and an average target price of $69.92.

Key Headlines Impacting IonQ

Here are the key news stories impacting IonQ this week:

• Positive Sentiment: Drug-discovery partnership validates IonQ’s technology. IonQ and QC Ware demonstrated a hybrid quantum-classical chemistry workflow using IonQ’s Forte trapped-ion system through Amazon Braket. The test produced enzyme active-site interaction-energy results within 4% of a benchmark, meeting the chemical-accuracy threshold cited for pharmaceutical research. The announcement expands IonQ’s potential applications beyond general quantum computing and could support future commercial demand. QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
• Positive Sentiment: IonQ’s platform is being integrated into advanced molecular modeling. QC Ware’s Promethium platform links GPU processing with IonQ Forte hardware, while access through Amazon Braket makes the workflow available through a major cloud-computing channel. This may improve IonQ’s visibility among pharmaceutical and enterprise customers. QC Ware and IonQ Demonstrate High-Precision Hybrid Quantum Workflow for Drug Discovery
• Neutral Sentiment: Analysts see substantial potential upside, but the target is not a new forecast catalyst. IonQ has a reported consensus price target of $69.92, well above the current trading range. However, the company remains unprofitable, with analysts expecting a full-year loss, so investors may require evidence that technical demonstrations translate into recurring revenue. IonQ Receives $69.92 Consensus Price Target from Analysts
• Negative Sentiment: Approaching warrant expiration raises dilution concerns. IonQ’s outstanding public warrants are scheduled to expire on September 30, 2026. Exercise of in-the-money warrants could provide cash to IonQ but increase the share count, potentially pressuring existing shareholders and contributing to near-term volatility. IonQ Warrants Expire September 30 as Investors Watch for Potential Dilution

IonQ Profile

IonQ, Inc engages in the development of general-purpose quantum computing systems in the United States. It sells access to quantum computers of various qubit capacities. The company makes access to its quantum computers through cloud platforms, such as Amazon Web Services (AWS) Amazon Braket, Microsoft's Azure Quantum, and Google's Cloud Marketplace, as well as through its cloud service. It also provides contracts associated with the design, development, and construction of specialized quantum computing hardware systems; maintenance and support services; and consulting services related to co-developing algorithms on quantum computing systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source